Gland Pharma shares jumped 12% to a 52-week high on August 11, 2026, following the release of its first-quarter results. The sharp rally has drawn contrasting assessments from major global brokerages, highlighting divergent views on the company's near-term trajectory.

Jefferies Turns Bullish

Jefferies upgraded Gland Pharma from "hold" to "buy," raising its target price to ₹3,350 per share from the previous ₹2,080. At the time of the upgrade, this target implied an upside of 25.6% from the stock's prior closing price.

Goldman Sachs Remains Bearish

On the opposing side, Goldman Sachs retained its "sell" rating on the stock. The firm did, however, raise its target price to ₹2,125 per share from the earlier ₹1,875, which still indicated a downside of approximately 20% from the previous close.

The gap of more than ₹1,200 between the two brokerages' targets underscores how differently they assess the company's earnings trajectory and growth runway. Such wide dispersion in analyst targets often reflects differing assumptions about pipeline strength, margin sustainability, and competitive positioning in key regulated markets.

Company Background

Gland Pharma is a Hyderabad-based pharmaceutical company specializing in sterile injectables and related drug delivery systems. The company operates across multiple therapeutic segments and serves both domestic and international markets, including the United States, Europe, and Canada. It is listed on Indian stock exchanges under the ticker GP14.

The company is known for its expertise in complex injectable formulations and contract manufacturing, positioning itself as a key player in the global injectables supply chain. Sterile injectables represent a high-barrier pharmaceutical segment requiring specialized aseptic manufacturing facilities and regulatory clearances from agencies such as the US FDA, factors that can limit new entrants and shape brokerages' long-term assessments of incumbents like Gland Pharma.

Source: CNBC-TV18 Markets